Katholieke Universiteit Leuven
Characterization of non-canonical EZH2 transcriptional complexes to identify new therapeutic targets in peripheral T cell lymphoma.
2023
Leuven
Research study by Marlies Vanden Bempt: Peripheral T cell lymphoma is a heterogeneous group of rare T cell malignancies. Currently, there are no effective therapies for PTCL other than chemotherapy, resulting in a survival rate of only 30%. I aim to investigate the transcriptional complexes formed by EZH2 and MYCN in PTCL, in order to gain more insight into the mechanism of action of these oncogenes. These new insights could lead to the identification of novel targets for therapy.